Patients With AERD Undergoing Aspirin Desensitization Clinical Trial
Official title:
The Metabolomics of Anaphylaxis
Metabolomics is the study of metabolic pathways and the unique biochemical molecules which
result from the regulatory response to physiological stressors, disease processes, or drug
therapy. By measuring changes in metabolite concentrations, the range of biochemical effects
and therapeutic intervention can be determined.
Aspirin exacerbated respiratory disease (AERD) is a chronic inflammatory disease
characterized by chronic rhinosinusitis, nasal polyposis, asthma, and airway reactivity to
aspirin and/or other nonsteroidal anti-inflammatory drugs (NSAIDs). This reaction to aspirin
during challenge/desensitization is equivalent to an allergic drug reaction however we are
able to evaluate these specific reactions in a controlled, clinical environment. This
population of patients undergoing aspirin desensitization is ideal for studying metabolomics
as serial blood sampling can be performed in patients before, during a reaction, and after
aspirin desensitization, thereby allowing each patient to serve as his or her own biological
control. The investigator hopes that this study of metabolomics will allow for better methods
of identifying anaphylaxis in the future.
n/a